Dulaglutide vs Tirzepatide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Dulaglutide
Once-weekly GLP-1 receptor agonist (Trulicity) approved for type 2 diabetes and cardiovascular risk reduction. Engineered as a GLP-1 analogue fused to a modified IgG4-Fc domain, which provides a ~5-day half-life and enables once-weekly subcutaneous dosing via a simple auto-injector pen with no reconstitution required.
Full profileTirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. Approved as Mounjaro (type 2 diabetes) and Zepbound (obesity), it produces greater weight loss than any approved GLP-1 monotherapy in clinical trials.
Full profile| Dulaglutide | Tirzepatide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | Trulicity, LY2189265 | LY3298176, Mounjaro, Zepbound |
| Evidence | FDA-approved | FDA-approved |
| Dosing range | 0.75mg–4.5mg mg, once weekly subcutaneous | 2.5mg–15mg mg, Once weekly subcutaneous injection |
| Administration | Subcutaneous injection (auto-injector pen) | Subcutaneous injection (abdomen, thigh, or upper arm) |
| Key side effects | Nausea (most common), Diarrhea, Vomiting, Abdominal pain | Nausea (most common, especially during titration), Vomiting, Diarrhea, Constipation |
| Cited sources | 2 references | 4 references |
Key differences
- Administration: Dulaglutide — Subcutaneous injection (auto-injector pen); Tirzepatide — Subcutaneous injection (abdomen, thigh, or upper arm).
- Frequency: Dulaglutide is typically once weekly subcutaneous; Tirzepatide is Once weekly subcutaneous injection.
- Research depth: this profile cites 2 sources for Dulaglutide vs 4 for Tirzepatide.
How each works
Dulaglutide
Dulaglutide's large molecular structure (fusion with IgG4-Fc) prevents renal filtration and extends half-life via FcRn recycling, enabling once-weekly dosing. The REWIND cardiovascular outcomes trial demonstrated significant reduction in major adverse cardiovascular events (MACE) in patients with or at risk for cardiovascular disease, establishing dulaglutide as a cardioprotective agent beyond glucose control.
Tirzepatide
The SURMOUNT-1 trial (N=2539) demonstrated up to 22.5% mean body weight reduction over 72 weeks at the 15mg dose — the highest efficacy ever recorded for a pharmaceutical weight loss agent at time of publication. The dual mechanism leverages GIP's potentiation of insulin secretion and adipose tissue effects alongside GLP-1's appetite suppression and gastric motility slowing. Head-to-head data (SURMOUNT-5) shows tirzepatide outperforms semaglutide 2.4mg for weight loss.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.